The stock price of Biofrontera Inc (NASDAQ: BFRI) has jumped by 6.05 compared to previous close of 0.61. Despite this, the company has seen a gain of 2.95% in its stock price over the last five trading days. globenewswire.com reported 2025-06-11 that WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according to which the two companies are in negotiations regarding a possible combination of the two companies or an adjustment of the license and supply agreement between them. The latter could result in the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and a reduction in the transfer price for Biofrontera Inc.’s licensed products sold in the US.
Is It Worth Investing in Biofrontera Inc (NASDAQ: BFRI) Right Now?
The 36-month beta value for BFRI is at 0.32. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BFRI is 8.07M, and currently, shorts hold a 2.58% of that float. The average trading volume for BFRI on June 12, 2025 was 140.19K shares.
BFRI’s Market Performance
BFRI stock saw a decrease of 2.95% in the past week, with a monthly decline of -5.00% and a quarterly a decrease of -29.52%. The volatility ratio for the week is 2.75%, and the volatility levels for the last 30 days are 5.18% for Biofrontera Inc (BFRI). The simple moving average for the past 20 days is 2.26% for BFRI’s stock, with a -31.43% simple moving average for the past 200 days.
BFRI Trading at -9.01% from the 50-Day Moving Average
After a stumble in the market that brought BFRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.79% of loss for the given period.
#####
#####
Stock Fundamentals for BFRI
Current profitability levels for the company are sitting at:
- -0.43 for the present operating margin
- 0.55 for the gross margin
The net margin for Biofrontera Inc stands at -0.3. The total capital return value is set at -2.89. Equity return is now at value -384.98, with -56.00 for asset returns.
Based on Biofrontera Inc (BFRI), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at -2.27. The debt to equity ratio resting at 10.37. The interest coverage ratio of the stock is 4.57.
Currently, EBITDA for the company is -14.44 million with net debt to EBITDA at -0.2. When we switch over and look at the enterprise to sales, we see a ratio of 0.24. The receivables turnover for the company is 9.42for trailing twelve months and the total asset turnover is 2.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
In conclusion, Biofrontera Inc (BFRI) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
